Featured Products
Our Promise to You
Guaranteed product quality, expert customer support
GRANTA-519
- Specification
- Recommended Products
Immunology: CD3 -, CD10 -, CD13 -, CD19 +, CD20 +, CD34 -, CD37 +, CD38 +, cyCD79a +, CD80 +, CD138
- Background
- Scientific Data
- Q & A
- Customer Review
- Product Information Sheet
GRANTA-519 cells are a well-known cell line that was established from the peripheral blood of a 58-year-old Caucasian woman in 1991. The blood sample was obtained at the time of relapse of a high-grade B-cell non-Hodgkin's lymphoma (B-NHL) that had undergone leukemic transformation from Mantle cell lymphoma (MCL). It is worth noting that the patient had a previous history of cervical carcinoma.
GRANTA-519 cells exhibit several features that are representative of high-grade B-NHL, including aggressive growth patterns, abnormal proliferation, and the ability to form tumors in immunodeficient mice. These cells are commonly used to investigate the genetic and molecular alterations associated with lymphoma transformation, as well as to explore potential therapeutic targets and treatment strategies.
Researchers have extensively characterized GRANTA-519 cells, which has led to a deeper understanding of the mechanisms driving lymphoma progression and resistance to standard therapies. These cells have been employed in various experimental assays to evaluate the efficacy of potential therapeutic agents, including chemotherapy drugs, targeted therapies, and immunotherapies. Such studies have aimed to identify novel treatment approaches and improve patient outcomes in high-grade B-NHL.
In Vitro Activity of CYC202 in Granta-519 Cells
MCL accounts for approximately 8% of all non-Hodgkin's lymphomas. CYC202 is a purine analog and a selective inhibitor of the cdk2-cyclin E as well as cdk7-cyclin H and cdk9-cyclin T. The activity of CYC202 was tested in MCL (Granta-519) cell lines. Granta-519 cells were assayed for cell viability after treatment with increasing concentrations of CYC202 using the MTT assay. The anti-proliferative effect of CYC202 was evaluated by measuring the growth rates of Granta-519 cells seeded at low density and treated with a drug dose corresponding to the IC50 for each cell line (Fig. 1). Treatment with CYC202 caused a time-dependent inhibition of cell growth by the cell viability assay.
To determine the effects of CYC202 on the cell cycle profile, the cell lines were treated with CYC202 for 24 h and 48 h with the corresponding IC50 drug concentrations. After 24 h of treatment with the IC50 dose of CYC202, an accumulation of cells in the G2-M phase was detected in Granta-519 cells (Fig. 2). Figure 3 shows the TUNEL assay results after 72 h of treatment with CYC202; apoptosis was present in Granta-519 cell lines.
Fig. 1 Growth curves of Granta-519 cells continuously exposed to the corresponding IC50 dose of CYC202. (Lacrima K, et al., 2005)
Fig. 2 Cell cycle alterations induced by CYC202 in Granta-519 cells. (Lacrima K, et al., 2005)
Fig. 3 Effect of CYC202 on the induction of apoptosis in Granta-519 cells. (Lacrima K, et al., 2005)
MRI is the gold-standard imaging modality for the detection of bone marrow involvement and the preferred imaging technique to rule out spinal cord compression in patients with multiple myeloma, whereas PET/CT provides valuable prognostic data and aids in the assessment of response to therapy.
GRANTA-519 cells provide researchers with a valuable tool for studying the biology, molecular mechanisms, and treatment options related to high-grade B-cell non-Hodgkin's lymphoma, specifically in cases of leukemic transformation from mantle cell lymphoma.
GRANTA-519 cells are used in various experimental assays to evaluate the efficacy and mechanisms of action of potential therapeutic agents, including chemotherapy drugs, targeted therapies, and immunotherapies. They are also employed to study lymphoma biology and to explore novel treatment approaches.
GRANTA-519 cells have been extensively studied to investigate the genetic and molecular alterations associated with lymphoma transformation. They have provided insights into the mechanisms driving lymphoma progression, treatment resistance, and potential therapeutic targets.
Average Rating: 4.7 | 3 Scientist has reviewed this product
Excellent
We uncovered the signaling pathways and cellular processes involved in the growth and survival of lymphoma cells. Creative Bioarray's cellular products are indispensable for experiments.
19 Feb 2023
Ease of use
After sales services
Value for money
Expected characterizations
I found the quality of the Granta-519 cell line to be excellent. The cells displayed the expected characteristics associated with high-grade B-NHL and leukemic transformation of mantle cell lymphoma, aligning with the intended research objectives.
02 Jan 2024
Ease of use
After sales services
Value for money
Valuable assistances
The responsive and knowledgeable customer support team at Creative Bioarray demonstrated a commitment to customer satisfaction and provided valuable assistance throughout the purchasing and experimental processes.
17 Feb 2024
Ease of use
After sales services
Value for money
Granta-519Customer Support & Price Inquiry
